JAMA
Meta-analysis of 16 trials of hemoglobin-based oxygen carriers (HBOCs) found a significantly increased risk of myocardial infarction (RR 1.59) and a trend toward increased mortality. Important safety context for patients considering synthetic blood alternatives.
Use of HBOCs was associated with a significantly increased risk of myocardial infarction (relative risk 1.59; 95% CI 1.02-2.49) and a trend toward increased risk of death (relative risk 1.30; 95% CI 0.98-1.74).